<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Technetium Tc-99m pentetate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Technetium Tc-99m pentetate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Technetium Tc-99m pentetate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="101538" href="/d/html/101538.html" rel="external">see "Technetium Tc-99m pentetate: Drug information"</a> and <a class="drug drug_patient" data-topicid="101539" href="/d/html/101539.html" rel="external">see "Technetium Tc-99m pentetate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58354652"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Draximage DTPA</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56724183"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Draximage DTPA</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F7789308"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Radiopharmaceutical</span></li></ul></div>
<div class="block dop drugH1Div" id="F58993880"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Measure dose with appropriate radioactivity calibration system immediately prior to administration. Do not administer more than 1 dose. Route of administration (IV vs inhalation) will vary with indication, and dosing units vary between weight-directed (mCi/<b>kg</b>) and fixed dose (mCi); use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ed9ef86-8c12-4ac5-b2fe-d29c6aadf7b2">Lung ventilation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lung ventilation:</b> Infants, Children, and Adolescents: Inhalation (via nebulizer): 25 mCi (925 MBq). For imaging performed prior to perfusion imaging, the target dose is at an imaging count rate of 10,000 to 50,000/minute; for imaging performed after perfusion imaging, target count rate should be ~3 times that of perfusion count rate.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58375801-0332-4bf4-9ed8-c064c8f6a7d4">Renal scintigraphy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal scintigraphy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>GFR estimation with no renal imaging:</b> Infants, Children, and Adolescents: IV: 0.2 to 0.5 mCi (7.4 to 18.5 MBq) followed by blood sampling.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Renal visualization and perfusion assessment: </b>Infants, Children, and Adolescents: IV: 0.1 to 0.2 mCi/<b>kg</b> (3.7 to 7.4 MBq/<b>kg</b>); minimum dose: 1 mCi (37 MBq); maximum dose: 5 mCi (185 MBq). Immediate dynamic imaging; static imaging 1 to 30 minutes after administration.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F58993896"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F58993925"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F28106656"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="101538" href="/d/html/101538.html" rel="external">see "Technetium Tc-99m pentetate: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Measure dose with appropriate radioactivity calibration system immediately prior to administration. Do not administer more than 1 dose. The recommended IV doses below are based on a 70 kg patient.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="91a27208-9f72-4358-88f6-b5cfa94442b1">Brain imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Brain imaging: IV:</b> 10 to 20 mCi (370 to 740 MBq). Immediate dynamic imaging; obtain at least 1 blood-pool image in same position as flow; delayed images may be obtained 1 hour later.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa1c1a47-519e-405b-8c90-98563c225364">GFR estimation with renal visualization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>GFR estimation with renal visualization:</b>
<b>IV:</b> 3 to 5 mCi (111 to 185 MBq). Immediate dynamic imaging; static imaging 1 to 30 minutes after administration.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75b2c72a-6d46-433d-8af9-3bb8ceebcb6b">GFR estimation with no renal imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>GFR estimation with no renal imaging: IV:</b> 0.2 to 0.5 mCi (7.4 to 18.5 MBq). Blood sampling only is performed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e212a1f4-dcc5-4235-89c8-c12385c3b011">Renal perfusion assessment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal perfusion assessment (with renal visualization):</b>
<b>IV:</b> 10 to 20 mCi (370 to 740 MBq). Immediate dynamic imaging; static imaging 1 to 30 minutes after administration.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ed9ef86-8c12-4ac5-b2fe-d29c6aadf7b2">Lung ventilation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lung ventilation: Inhalation (via nebulizer):</b> 25 to 50 mCi (925 to 1,850 MBq); to achieve a lung dose of ~0.5 to 1 mCi (18.5 to 37 MBq). For imaging performed prior to perfusion imaging, the target dose is achieved after 3 to 5 minutes of inhalation or at an imaging count of 50,000 to 100,000/minute; for imaging performed after perfusion imaging, target count rate should be ~3 times that of perfusion count rate.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990403"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987579"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F28106649"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, anaphylaxis, angioedema, chills, cyanosis, dizziness, erythema, headache, hypersensitivity reaction, hypertension, hypotension, nausea, pruritus, skin rash, syncope, tachycardia, throat irritation, urticaria, vomiting, wheezing</p></div>
<div class="block coi drugH1Div" id="F28106679"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to technetium Tc 99m pentetate or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F28106647"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospasm: With inhalation use, may result in acute bronchospasm especially in patients with heightened bronchoreactivity (eg, asthma or other lung or allergic disorders); monitor all patients for bronchoconstriction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (including anaphylaxis) have been reported; appropriate equipment and personnel to manage hypersensitivity should be available during use. Monitor for hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation accumulation: Tc 99m administration contributes to the patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Use the lowest dose necessary for imaging. Ensure safe handling to minimize radiation exposure to the patient and health care providers. Risk is greater with pediatric patients due to greater radiosensitivity and longer life expectancy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. <b>Note: </b>Supplied as a kit for the preparation of the product, technetium Tc 99m pentetate, not the final product itself. Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Patients receiving kidney imaging should be adequately hydrated prior to dosing; instruct patients to void frequently for 4 to 6 hours following administration to decrease radiation exposure to the bladder.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lung ventilation study: In patients with obstructive pulmonary disease there may be deposition of particles in the proximal airways which may influence the image quality and interfere with diagnostic interpretation; careful nebulizer use is essential to assure optimal particle delivery and ensure diagnostic quality. Consider additional diagnostic options if particle deposition occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Risk for misinterpretation: Image interpretation errors may occur with Tc 99m pentetate. Deposition of particles in the proximal airways may influence image quality and diagnostic interpretation; optimal particle delivery is essential therefore careful use of the nebulizer is important to ensure diagnostic quality. Consider additional diagnostic options if interference occurs.</p></div>
<div class="block foc drugH1Div" id="F58354653"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Kit, Intravenous:</p>
<p style="text-indent:-2em;margin-left:4em;">Draximage DTPA: Lyophilized pentetic acid mixture to be combined with sodium pertechnetate Tc99m injection solution (30s)</p></div>
<div class="block geq drugH1Div" id="F59051942"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;">No</p></div>
<div class="block dinfoc drugH1Div" id="F56724184"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Kit, Intravenous:</p>
<p style="text-indent:-2em;margin-left:4em;">Draximage DTPA: Lyophilized pentetic acid mixture to be combined with sodium pertechnetate Tc99m injection solution (10s)</p></div>
<div class="block admp drugH1Div" id="F58993927"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding, including syringe shields, when handling.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Contents of vial are not for direct IV injection; only reconstituted technetium Tc 99m pentetate may be administered IV. See manufacturer's labeling for complete administration procedure. Ensure adequate hydration before and after administration; void frequently for 4 to 6 hours post administration to minimize bladder radiation exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">Inhalation: Contents of vial are not for direct inhalation; only reconstituted technetium Tc 99m pentetate may be used for inhalation; a disposable nebulizer is required for administration. Rinse mouth and expectorate after use to minimize mouth and esophagus radiation exposure.</p></div>
<div class="block adm drugH1Div" id="F28106659"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Inhalation: A disposable nebulizer is required. Rinse mouth and expectorate after use to minimize mouth and esophagus radiation exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Not for direct IV injection; only reconstituted technetium Tc 99m pentetate may be administered IV. See manufacturer's prescribing information for complete administration procedure. Ensure adequate hydration before and after administration; void frequently for 4 to 6 hours post administration to minimize bladder radiation exposure.</p>
<p style="text-indent:0em;margin-top:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding when handling.</p></div>
<div class="block sts drugH1Div" id="F28106653"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact and reconstituted vials at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). After labeling with Tc-99m, store in a lead shield and discard after 12 hours.</p></div>
<div class="block usep drugH1Div" id="F53570394"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Inhalation: Lung ventilation imaging evaluation of pulmonary embolism when used in combination with perfusion imaging (FDA approved in all ages).</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Radiopharmaceutical imaging agent used for renal visualization for renal perfusion assessment and GFR estimation (FDA approved in all ages) and for brain imaging (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F7734583"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F28407238"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F28407235"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53623758"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Pregnancy status should be evaluated prior to use in patients who could become pregnant (SNM 2010).</p></div>
<div class="block pri drugH1Div" id="F28106644"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Technetium Tc 99m can be detected in fetal tissue; the amount depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein 1999). The diagnostic use of technetium Tc 99m pentetate in pregnant patients has been reported (Goldstein 1988; Griffith 1992). Increased fluid intake and frequent voiding can reduce potential fetal exposure (Adelstein 1999; Goldstein 1988; ICRP 2000).</p>
<p style="text-indent:0em;margin-top:2em;">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (ACR-SPR 2018; Adelstein 1999; ICRP 2000; SNM 2010). Guidelines are available as to when lung scintigraphy for the diagnosis of pulmonary embolism should be done in pregnant patients (Leung 2011).</p></div>
<div class="block pha drugH1Div" id="F51090073"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Radioactive diagnostic agent which decays by isomeric transition to emit a photon that can be detected by imaging.</p></div>
<div class="block phk drugH1Div" id="F28106681"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: IV: Vss: 17 L; distributed throughout extracellular fluid space</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Inhalation: ~70%</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: IV: ~4% to 10%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: 2.1 hours; Decay half-life: 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Inhalation: &lt;2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: IV: Urine (~100%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F27774699"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Technescan dtpa</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Technescan dtpa</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-10331526">
<a name="10331526"></a>Adelstein SJ. Administered radionuclides in pregnancy. <i>Teratology</i>. 1999 Apr;59(4):236-239. doi:10.1002/(SICI)1096-9926(199904)59:4&lt;236::AID-TERA9&gt;3.0.CO;2-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-pentetate-pediatric-drug-information/abstract-text/10331526/pubmed" id="10331526" target="_blank">10331526</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American College of Radiology (ACR), Society for Pediatric Radiology (SPR), and Society of Nuclear Medicine (SNM). ACR-SPR-SNM practice guideline for the performance of adult and pediatric radionuclide cystography. 2010. http://snmmi.files.cms-plus.com/docs/Radionuclide_Cystography_1382732076756_9.pdf
                  </div>
</li>
<li>
<div class="reference">
                  American College of Radiology (ACR), Society for Pediatric Radiology (SPR). ACR–SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation (resolution 39). Revised 2018. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Pregnant-Pts.pdf?la=en. Accessed February 24, 2020.</div>
</li>
<li>
<div class="reference">
                  Draximage DTPA (technetium Tc 99m pentetate) [prescribing information]. Kirkland, Quebec, Canada: Jubilant DraxImage Inc; June 2023</div>
</li>
<li>
<div class="reference">
                  Draximage DTPA (technetium Tc 99m pentetate) [product monograph]. Kirkland, Quebec, Canada: Jubilant DraxImage Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3042923">
<a name="3042923"></a>Goldstein HA, Ziessman HA, Fahey FH, et al. Renal Scans in Pregnant Transplant Patients. <i>J Nucl Med</i>. 1988;29(8):1364-1367.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-pentetate-pediatric-drug-information/abstract-text/3042923/pubmed" id="3042923" target="_blank">3042923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1395349">
<a name="1395349"></a>Griffith D, Alexander M, Gelman R, et al. Normal Uptake in a Gravid Uterus on Tc-99m DTPA Imaging. <i>Clin Nucl Med</i>. 1992;17(9):736-737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-pentetate-pediatric-drug-information/abstract-text/1395349/pubmed" id="1395349" target="_blank">1395349</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Harding LK, Bossuyt S, Pellet C, et al. Recommendations for Nuclear Medicine Physicians Regarding Breastfeeding Mothers. <i>Eur J Nucl Med</i>. 1995;22(5)BP17.</div>
</li>
<li>
<div class="reference">
                  International Atomic Energy Agency. <i>IAEA Safety Standards for Protecting People and the Environment: Radiation Protection and Safety in Medical Uses of Ionizing Radiation. Specific Safety Guide No. SSG-46</i>. IAEA; 2018. https://www​.iaea.org​/publications/11102/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11108925">
<a name="11108925"></a>International Commission on Radiological Protection (ICRP). Pregnancy and Medical Radiation. <i>Ann ICRP</i>. 2000;30(1):iii-viii, 1-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-pentetate-pediatric-drug-information/abstract-text/11108925/pubmed" id="11108925" target="_blank">11108925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086989">
<a name="22086989"></a>Leung AN, Bull TM, Jaeschke R, et al. An Official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guideline: Evaluation of Suspected Pulmonary Embolism in Pregnancy. <i>Am J Respir Crit Care Med</i>. 2011;184(10):1200-1208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-pentetate-pediatric-drug-information/abstract-text/22086989/pubmed" id="22086989" target="_blank">22086989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31107104">
<a name="31107104"></a>Mitchell KB, Fleming MM, Anderson PO, Giesbrandt JG; Academy of Breastfeeding Medicine. ABM Clinical Protocol #31: radiology and nuclear medicine studies in lactating women. <i>Breastfeed Med</i>. 2019;14(5):290‐294. doi:10.1089/bfm.2019.29128.kbm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-pentetate-pediatric-drug-information/abstract-text/31107104/pubmed" id="31107104" target="_blank">31107104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2645546">
<a name="2645546"></a>Mountford PJ, Coakley AJ. A Review of the Secretion of Radioactivity in Human Breast Milk: Data, Quantitative Analysis and Recommendations. <i>Nucl Med Commun</i>. 1989;10(1):15-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-pentetate-pediatric-drug-information/abstract-text/2645546/pubmed" id="2645546" target="_blank">2645546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8162938">
<a name="8162938"></a>Rubow S, Klopper J, Wasserman H, et al. The Excretion of Radiopharmaceuticals in Human Breast Milk: Additional Data and Dosimetry. <i>Eur J Nucl Med</i>. 1994;21(2):144-153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-pentetate-pediatric-drug-information/abstract-text/8162938/pubmed" id="8162938" target="_blank">8162938</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Society of Nuclear medicine (SNM). Society of Nuclear Medicine procedure guideline for general imaging. Version 6.0. Revised 2010. http://s3.amazonaws.com/rdcms-snmmi/files/production/public/docs/General_Imaging_Version_6.0.pdf. Accessed July 22, 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 143846 Version 2.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
